Background: Casopitant mesylate is a novel, oral neurokinin-1 receptor antagonist with demonstrated antiemetic efficacy. We conducted a randomized, double-blind, controlled phase II trial to evaluate three casopitant doses as part of a triple-therapy regimen for the prevention of nausea and vomiting associated with high-dose cisplatin. The aim of the study was to detect a dose response.
introduction Treatment with the highly emetogenic chemotherapy (HEC) agent cisplatin produces emesis in >90% of patients in the absence of prophylactic antiemetics [1] . With effective prophylaxis, acute emesis can be prevented for the majority of patients, but delayed emesis remains a therapeutic challenge. The addition of the neurokinin-1 (NK1) receptor antagonist aprepitant to the two-drug combination of a 5-hydroxytryptamine-3 serotonin receptor antagonist and dexamethasone improves complete response (CR) rates (no vomiting, no retching, and no use of rescue medication) after cisplatin-based therapy, and this three-drug regimen is now recommended for patients receiving HEC [1] [2] [3] . Despite the improvement afforded with this regimen, 27% to 37% of patients still experience vomiting or require rescue therapy after cisplatin, demonstrating the need for continued clinical research in this setting [4] [5] [6] [7] .
Casopitant mesylate is a novel, potent, selective NK1 receptor antagonist with demonstrated antiemetic activity in vivo [8, 9] . In ferret models, a combination of casopitant and ondansetron was superior to either agent given alone for the prevention of acute cisplatin-induced emesis, but only casopitant was effective at rescuing animals from established, delayed cisplatin-induced emesis [8, 9] . Casopitant has been studied in phase II trials in combination with ondansetron for the control of postoperative nausea and vomiting at a dose of 50 mg [10] . Reported rates of adverse events between the combination and ondansetron monotherapy were similar and included headache, constipation, dizziness, and pruritis.
We conducted a randomized, double-blind, controlled phase II trial to evaluate the safety and efficacy of casopitant at three dose levels in combination with a standard ondansetron/ dexamethasone (Ond/Dex) regimen for the prevention of nausea and vomiting associated with the first cycle of cisplatinbased chemotherapy. Two exploratory arms were included in this trial: one to assess the activity of a single dose of casopitant relative to the 3-day dosing regimens and the other to further assess the relative activity of aprepitant-based therapy within the context of this randomized trial.
patients and methods design
All patients gave written informed consent before participation, and the study was conducted in accordance with good clinical practice, all applicable regulatory requirements, and the guiding principles of the Declaration of Helsinki.
patients
Eligible patients were chemonaive, >18 years, diagnosed with a malignant solid tumor, and scheduled to receive at least one course of cisplatin, at a dose ‡70 mg/m 2 per cycle. Patients were required to have a Karnofsky
Performance Scale score of ‡70 and adequate hematologic and metabolic status, defined as white blood cells >3000/mm 3 , platelets >100 000/mm 3 , and serum creatinine <1.5 mg/dl (132.6 lmol/l). Eligible patients demonstrated normal liver function (laboratory values for aspartate aminotransferase and/or alanine aminotransferase £2.5· the upper limit of normal without known liver metastases or £5.0· the upper limit of normal with liver metastases).
Patients were not eligible if they had previously received cytotoxic chemotherapy or an NK1 receptor antagonist or were scheduled to receive (i) cisplatin on >1 day per cycle, (ii) adjuvant cyclophosphamide-based chemotherapy, (iii) bone marrow transplantation and/or stem-cell rescue with this chemotherapy course, or (iv) moderate or HEC within the 48 h before study drug initiation. Abdominal or pelvic radiation was not allowed from 7 days before to 6 days after study medication initiation. Patients with known central nervous system metastases were ineligible unless successfully treated with excision or radiation and stable for at least 1 week before receiving the first dose of study medication.
Patients receiving other antiemetics, agents with antiemetic potential, or who had an alternative etiology for emesis and nausea (e.g. gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, and active peptic ulcer) were excluded from the study. Systemic corticosteroid therapy was not to be initiated (other than taxane premedication) within 72 h before the first dose of study medication. Opioid narcotics for cancer pain were permitted if the dose had been stable for at least 7 days and the patient had not experienced nausea or emesis as a side-effect. Because casopitant is a substrate of CYP3A [11, 12] , patients were ineligible if they had taken strong or moderate inhibitors of CYP3A4 and CYP3A5 within 2-14 days of the first dose of study medication or inducers of CYP3A4 within 14 days of the first dose of study medication. The use of other investigational drugs within 30 days or five half-lives before study drug initiation or during the study was not allowed. Finally, patients with emesis (i.e. vomiting and/or retching) or clinically significant nausea experienced in the 24 h before receiving the first dose of study medication were also excluded.
treatment
Patients were centrally randomly assigned to one of the six treatment groups (Table 1) ; randomization was stratified by gender. Blinding was maintained in all groups with the use of matching placebos (tablets for casopitant and dexamethasone and capsules for aprepitant). The research pharmacist, the investigator, and the patient could not distinguish active and placebo treatments by appearance.
All patients received a single i.v. infusion ( ‡15 min) of ondansetron 30 min before cisplatin. Oral dexamethasone study medication was administered 30 min before cisplatin on day 1 and continued on days 2-4. Patients receiving a taxane received corticosteroids in accordance with usual institutional practice, rather than as described in Table 1 , as long as the dosage provided adequate antiemetic coverage in line with consensus guidelines [2] . Oral casopitant and aprepitant study medications were administered 1 h before the start of cisplatin therapy on day 1 and repeated on the mornings of days 2 and 3. Patients in the control arm (group 1) received ondansetron, dexamethasone, and placebo. Patients in primary treatment arms (group 2, group 3, and group 4) received Ond/Dex combined with casopitant 50, 100, and 150 mg, respectively, for 3 days. In the exploratory arm (group 5), a single 150-mg dose of casopitant was added to the Ond/Dex regimen, and in the positive control arm (group 6), aprepitant for 3 days was added to the standard Ond/Dex combination. Due to the potential for increased exposure to dexamethasone when given in combination with casopitant or aprepitant, the dexamethasone dose in arms 2-6 was reduced to achieve dexamethasone exposure similar to that in arm 1.
Cisplatin was administered as a single i.v. dose over 1-4 h. When given in combination with agents of moderate to high emetogenic potential, cisplatin was to be administered first, with the administration of other agents initiated and completed within 6 h of the start of cisplatin. Agents of low emetogenic potential could be administered without regard to the cisplatin infusion. Taxanes were administered on study day 1.
Rescue antiemetic medication was administered when medically indicated if three emetic episodes occurred within a 15-min period, at physician discretion, or at any time upon patient request. The choice of rescue antiemetic medication was left to the discretion of the investigator, with the exception of NK1 receptor antagonists, which were prohibited. assessments A patient diary was used to capture all efficacy and safety data during the 120-h assessment phase. Beginning on day 1, patients recorded their baseline level of nausea and assessment of emetic episodes in the previous 24 h. Nausea was evaluated with a 0-100 mm visual analog scale (VAS), where 0 = 'No Nausea' and 100 = 'Nausea as bad as it can be'. On days 2-5, patients recorded nausea ratings and emetic episodes for the preceding 24 h each morning just before taking the morning study medications. Use of antiemetic rescue medication was also documented.
The primary end point of the study was the proportion of patients in groups 1-4 who achieved a CR, defined as no vomiting, no retching, no rescue therapy, and no premature discontinuation from the study, during a 120-h evaluation period following the first cycle of HEC, using an intentto-treat (ITT) analysis. Rates of CR during the acute (0-24 h) and delayed (24-120 h) phases were also evaluated in the ITT population. Patients who failed in the acute phase were considered failures in the delayed phase analysis for CR. As such, results for overall and delayed phase CR are indistinguishable.
Secondary end points included the rates of (i) complete protection (meets criteria for CR plus maximum nausea <25 mm on the VAS), (ii) total control (meets criteria for CR plus maximum nausea <5 mm on the VAS), (iii) no vomiting (defined as no vomiting or retching; could include patients who received rescue therapy), (iv) no nausea (maximum nausea < 5 mm on the VAS), and (v) no significant nausea (maximum original article Annals of Oncology nausea <25 mm on the VAS) during the overall (0-120 h), acute (0-24 h), and delayed (24-120 h) phases following the initiation of HEC. Median times to emesis and rescue were also determined.
Safety assessment included the results of routine physical examination, vital signs, electrocardiogram monitoring, routine clinical laboratory tests, clinical monitoring and/or observation, and adverse event reporting. Adverse events were captured by the study coordinators, who telephoned each patient on days 2-5 and graded any events according to the National Cancer Institute-Common Toxicity Criteria, version 3.
statistical analysis
The primary aim of this study was to detect a dose response. Testing was not based on comparisons strictly against placebo; a standard approach of testing for the presence of a nonzero linear trend was used. If an overall trend was discovered using data from all active doses and placebo, then subsequent ordinal contrast tests were used in an iterative fashion to test for a significant nonzero linear trend following the removal of the highest dose in the iteration. Therefore, no direct comparisons to placebo were carried out, unless all investigational doses were removed except the lowest dose.
A total of 492 patients was calculated to be sufficient to detect a 25% improvement in CR rates during the first 120 h at the two-sided level of significance of 5%, assuming a monotonic dose-response trend. The predicted rates of CR were 52% (group 1), 60% (group 2), 68% (group 3), and 77% (group 4). Using the Cochran-Armitage trend test for linear trend in the dose response [13] , 69 patients per group would be required to detect a monotonic trend with 90% power. The SAS-based procedure MULTTEST was used to test the null hypothesis. The primary analysis was stratified by gender.
Following significance of the overall trend test, to identify the doses that exhibited a treatment effect, ordinal contrasts were fitted using the MULTTEST procedure. Contrasts were fit by excluding the highest dose until the test was no longer statistically significant; the highest dose at which the ordinal contrasts retained statistical significance was to be considered the minimally effective 3-day dose.
For the end points of complete protection, total control, vomiting, significant nausea, and nausea, the proportion of subjects who achieved each efficacy end point was compared between the control group and each of the treatment groups as described for the primary end point. Time-toevent end points (time to first emetic event and first rescue medication) were summarized using Kaplan-Meier curves.
results
A total of 493 patients were accrued from 47 centers in 18 countries (Figure 1 ). The subset of 328 patients randomly assigned to one of the first four treatment groups comprises the ITT population for the primary efficacy analyses ( Table 2) . Due to the potential for increased exposure to dexamethasone when given in combination with casopitant or aprepitant, the dexamethasone doses in groups 2-6 were modified to achieve dexamethasone exposure similar to that in group 1. Dex, dexamethasone; BID, twice a day; Ond, ondansetron; Cas, casopitant; PBO, placebo; Apr, aprepitant; QAM, in the morning; QPM, in the evening. Cas, casopitant; Apr, aprepitant; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
original article
Annals of Oncology
Population demographics were similar across all treatment groups. The most common diagnoses were lung (non-small cell and small cell), ovarian, and head and neck cancer. More males were enrolled than females (67% males). The average age of all patients was 57.1 years, and most had been diagnosed within the month before study enrollment. The chemotherapy agents most frequently given with cisplatin were of low emetogenic potential and included etoposide, gemcitabine, and vinorelbine.
efficacy
All casopitant treatment regimens (1-and 3-day) were clinically effective. In the primary analysis, the CR rate in group 1 was 60% versus 76% with group 2, 86% with group 3, and 77% with group 4 (Cochran-Armitage trend test P value: P = 0.0036). Ordinal contrast statistical testing indicated that all 3-day dose regimens were effective (P £ 0.0155), i.e. a minimally effective 3-day dose had not been determined (Table 3) . Rates of CR were generally similar in the acute phase (P for trend = 0.289), with a statistically significant and clinically meaningful improvement seen in the casopitant arms during the delayed phase (Table 3 ).
In the exploratory analyses, the single-dose casopitant regimen (group 5) produced a statistically significant improvement in CR relative to control ( Table 3 ). The CR rate of 74.7% over the first 120 h following chemotherapy was significantly higher due mainly to effectiveness in the delayed phase from 24-120 h [15.2% increase in CR rates for overall and delayed phase relative to group 1; 95% confidence interval (CI) 1.1-29.2]. The 3-day aprepitant regimen (group 6) produced a CR rate of 72% overall and in the delayed phase.
The incidence of vomiting was significantly reduced with casopitant in the primary analysis, and the time to first emetic event was significantly delayed relative to group 1 (P = 0.0029; Figure 2 ). In group 1, 64% of patients reported 'no vomiting' in the first 120 h after chemotherapy versus 78%, 89%, and 78% in group 2, group 3, and group 4, respectively (P = 0.0122 for monotonic trend). All doses of casopitant were superior to control (ordinal contrast P values: 0.0313, 0.0001, and 0.0122, respectively). As in the primary analysis, the effect on vomiting was most apparent in the delayed phase (monotonic trends: acute phase, P = 0.4783 and delayed phase, P = 0.0122). The single-dose casopitant regimen also resulted in a statistically significant improvement in the no vomiting end point over the 120-h period (78% versus 64%, respectively; difference in rates 214.0%, 95% CI 227.6 to 20.5). The rate of no vomiting within the 3-day aprepitant group was 79%.
No differences were observed in the incidence of nausea or significant nausea among groups in the primary analysis. Rates of no nausea from 0-120 h ranged from 39% in group 1 to 42% in groups 2-4. Rates of no significant nausea ranged from 54% in group 1 to 62% in groups 2-4. Accordingly, the rates of total control and complete protection from 0-120 h did not differ significantly among treatment groups. Similar to the 3-day casopitant regimens, there were no significant differences between group 5 and group 1 with respect to rates of no nausea (42% versus 39%), no significant nausea (55% versus 54%), complete protection (47% versus 42%), and total control (40% versus 32%) over 0-120 h. Results were generally similar with group 6 for no nausea (37%), no significant nausea (54%), complete protection (49%), and total control (35%).
Lesser than 10% of patients in each arm required rescue medication during the evaluation period (8% with group 1 versus 9%, 3%, and 4% in groups 2-4, respectively; P = 0.0865 for monotonic trend). There were no differences in the time to first rescue medication use across groups (P = 0.2162, log rank). Five patients from group 5 (6%) and seven from group 6 (8.5%) also required rescue medication during 0-120 h.
safety
The safety population consists of the 488 patients who received at least one dose of study medication. Table 4 describes the most common adverse events reported in all treatment groups, regardless of causality. Nausea and neutropenia were the most commonly reported events, with incidences ranging from 11% to 17% across treatment groups. There were no notable acknowledgements
